<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748939</url>
  </required_header>
  <id_info>
    <org_study_id>NTWCShingrixstudy</org_study_id>
    <nct_id>NCT04748939</nct_id>
  </id_info>
  <brief_title>Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT</brief_title>
  <official_title>Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tuen Mun Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind randomized controlled trial on the safety and immunogenicity of the&#xD;
      recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases&#xD;
      undergoing immunosuppressive or biologic/targeted DMARD therapies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind randomized controlled trial on the safety and immunogenicity of the&#xD;
      recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases&#xD;
      undergoing immunosuppressive or biologic/targeted DMARD therapies.&#xD;
&#xD;
      Duration of study: 60 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind for the identity of the drugs</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>humoral immune response to Shingrix</measure>
    <time_frame>week 12 (compared with baseline)</time_frame>
    <description>proportion of patients with 4x fold increase in anti-gE antibody titer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response</measure>
    <time_frame>week 52</time_frame>
    <description>proportion of patients with 4x fold increase in anti-gE antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>7 days after injection</time_frame>
    <description>solicited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>4 weeks after injection</time_frame>
    <description>unsolicited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>flares of underlying diseases</measure>
    <time_frame>week 26 and 60</time_frame>
    <description>disease flares</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>herpes zoster infection</measure>
    <time_frame>week 60</time_frame>
    <description>herpes zoster infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cell mediated response to vaccine</measure>
    <time_frame>week 12 from baseline</time_frame>
    <description>in 40 patients (20 from each arm); number of IFNγ-secreting CD4+ T cell colonies on ELISPOT assay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Shingrix vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline injection (0.5mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant subunit herpes zoster vaccine</intervention_name>
    <description>vaccine administration</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>vaccine</arm_group_label>
    <other_name>Shingrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of rheumatic or immune-mediated diseases eg. systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis,&#xD;
             inflammatory myopathies, ANCA-related and large vessel vasculitides&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Active disease requiring the following immunosuppressive regimens:&#xD;
&#xD;
               1. Prednisolone ≥0.6mg/kg/day ± intravenous pulse methylprednisolone, mycophenolate&#xD;
                  mofetil or the calcineurin inhibitors&#xD;
&#xD;
               2. Cyclophosphamide (intravenous pulses or daily oral)&#xD;
&#xD;
               3. B-cell depleting biological agents eg. rituximab, belimumab&#xD;
&#xD;
               4. Anti-TNFα biological agents eg. infliximab, etanercept, adalimumab, golimumab,&#xD;
                  certolizumab&#xD;
&#xD;
               5. Anti-interleukin-6 biological agents eg. tocilizumab, sarilumab&#xD;
&#xD;
               6. Other biological agents eg. abatacept, ustekinumab, secukinumab, ixekizumab&#xD;
&#xD;
               7. The Janice kinase inhibitors (JAKis) eg. tofacitinib, baricitinib, upadacitinib,&#xD;
                  filgotinib&#xD;
&#xD;
          4. Female patients with reproductive potential are allowed to participate in this study&#xD;
             provided that they are willing to practice contraception for until at least 12 months&#xD;
             after vaccination&#xD;
&#xD;
          5. Willing to comply with all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection, including upper respiratory tract infection&#xD;
&#xD;
          2. Active herpes zoster infection&#xD;
&#xD;
          3. Active untreated tuberculosis&#xD;
&#xD;
          4. Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          5. History of HZ or varicella vaccination in the past&#xD;
&#xD;
          6. History of allergy to any vaccines&#xD;
&#xD;
          7. Patients who are pregnant or plan to become pregnancy within one year of study entry&#xD;
&#xD;
          8. Pregnant or lactating women&#xD;
&#xD;
          9. Patients who cannot give a written consent (mentally incapable or illiterate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi Chiu Mok</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuen Mun Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chi Chiu Mok, MD, FRCP</last_name>
    <phone>852-37677518</phone>
    <email>ccmok2006@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Becky Fong</last_name>
    <phone>852-24685111</phone>
    <email>becky_fongls@yahoo.com.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medicine, Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 7, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuen Mun Hospital</investigator_affiliation>
    <investigator_full_name>Chi Chiu Mok</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>rheumatic diseases</keyword>
  <keyword>immunosuppressive</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>biologics</keyword>
  <keyword>targeted DMARDs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

